Γ—

Tag: Partial Cellular Reprogramming

A team led by renowned Harvard geroscientists David Sinclair and Vadim Gladyshev has reported successful chemically induced partial cellular reprogramming in vitro. The researchers have also developed a novel cellular rejuvenation assay [1]. Smaller than proteins Complete cellular reprogramming using the Yamanaka factors was first accomplished more than ten years ago [2]. Those four proteins,...
Mouse DNA
A preprint published in bioRxiv by scientists working at Rejuvenate Bio has described how gene therapy that allows for OSKM expression can be used to increase the lifespans of mice. A new handle on old problems The researchers begin this study with a discussion of the known problems of aging research. They bring up the...
Computer cell
Turn.bio has announced that its proprietary cellular reprogramming technology was able to significantly increase the proliferative and cytotoxic potential of premanufactured CAR-T cells in vitro. Turn.bio, a developer of mRNA-based cellular reprogramming technologies, has announced preliminary results from its current trial. The announcement was made by the company's co-founder, Prof. Vittorio Sebastiano, at the New...
Powerful mixture
A preprint published in bioRxiv has detailed how partial reprogramming through two small molecules can rejuvenate human cells as well as C.elegans, a common model of aging. Beyond OSKM This paper begins with a discussion of the four well-known Yamanaka reprogramming factors (OSKM) that cause cells to revert to a previous epigenetic state, citing previous...
Vittorio Sebastiano
Vittorio Sebastiano is an Associate Professor (Research) of Obstetrics and Gynecology at Stanford University and one of the most prominent scientists in the emerging field of cellular reprogramming. He is also co-founder and Scientific Advisory Board Chairman of Turn Biotechnologies, a cellular rejuvenation company based on the research done in Sebastiano’s Stanford lab. Turn recently...
Yuri Deigin Interview
In a recent press release, YouthBio Therapeutics announced that it has left stealth mode. YouthBio is a self-proclaimed longevity biotech company with a focus on developing gene therapies that reverse the epigenetic alterations that cause us to age. The company is hoping to reverse cellular aging in people through partial cellular reprogramming. This approach reverses...